Innovation centre opens
PerkinElmer, Inc., (Waltham, Massachusetts, USA) has built a personalized health innovation centre of excellence.
PerkinElmer, Inc., (Waltham, Massachusetts, USA) has built a personalized health innovation centre of excellence. The centre will focus on accelerating scientific innovation to help researchers who are working to eradicate disease and extend the quality and longevity of life.
The centre will bring together leaders from PerkinElmer’s chemistry, biochemistry, cell biology, molecular biology and reagent development R&D teams. They will focus on the development of applications solutions in genomics, imaging, biomarkers, biotherapeutics, targeted small molecule development and cell‑based assay solutions. The centre will also showcase a complete solutions-based demonstration laboratory for customers and collaborators.
The centre will be located at the company’s facility in Hopkinton, Massachusetts, USA, and is hoped to be fully operational by late 2012.Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, said, “We are delighted to establish our new centre of excellence, which will serve as an exciting example of PerkinElmer’s commitment to, and culture of, innovation. The expertise promoted by the centre will help bring novel and disruptive solutions to our customers, aiding their research in next generation treatments, early detection and disease prevention.”
For more information please visit www.perkinelmer.comThis story originally appeared in The Column. Click here to view that issue.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
